Jefferies Maintains Buy on Elevance Health, Lowers Price Target to $391

Benzinga Newsdesk www.benzinga.com Negative 47.9%

Neg 47.9% Neu 0% Pos 0%

Jefferies analyst David Windley maintains Elevance Health (NYSE:ELV) with a Buy and lowers the price target from $395 to $391.